Medical Aesthetics Market Growth Continues to Shine in Healthcare Industry - Seite 2

"Milestone conducted an extensive survey of over 150 medical professionals, including both plastic surgeons and cosmetic dermatologists. The physicians surveyed conduct regular botulinum toxin injections and are decision makers regarding the purchase of equipment and devices for their practice. Based on the results of the study, which indicated dissatisfaction with the current syringe-based technique, these medical professionals indicated a strong desire for improvement in the ability to inject precise dosage units and to minimize patient discomfort.

"As a result, we proceeded with the development of a new cosmetic injection instrument that allows the clinician to inject accurate doses with the precision of a stylus pen that is designed for comfort and superior tactile feel. Each injection is verified with audible sound feedback confirming unit dose and each injection is documented with an electronic record," stated Ms. Bernhard.

Ms. Bernhard concluded, "I am pleased to report we have now completed the design process and manufactured a set of fully functional pre-production devices. We have also completed a series of multi-state human factors studies with targeted customers. Based on the positive outcome, we are moving forward aggressively towards the commercial launch of our cosmetic instrument, starting first in Europe. Shortly thereafter, we plan to launch the product in the U.S. and across Asia. The cosmetic market represents a sizable and potentially lucrative market.  Moreover, most procedures are private pay and do not require reimbursement, which will help to further accelerate our commercialization timeline."

In other healthcare developments and market performances of note:

Allergen plc (NYSE: AGN) closed up slightly on Friday trading over 2.8 million by the market close. The company earlier this year received the US Food and Drug Administration (FDA) approval for the use of Botox for the temporary improvement of moderate-to-severe forehead lines.  The latest approval makes the brand the first and only neurotoxin to be indicated for three facial treatment areas. It has already been approved for the treatment of "crow's feet" and glabellar lines.